Polaryx Therapeutics Common Stock Overview
Valuation check: PLYX's ROE is -62.61%, below the Healthcare sector average of 22.13%.
Get informed when a big investor buys or sells
+ Follow-62.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Polaryx Therapeutics Common Stock (PLYX) currently reports a ROE of -62.61%. That is below the Healthcare sector average of 22.13%. Use the charts on this page to explore Polaryx Therapeutics Common Stock's ROE history and peer comparisons.
Polaryx Therapeutics Common Stock's ROE of -62.61% is lower than the Healthcare sector average of 22.13%. That is roughly 383.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Polaryx Therapeutics Common Stock's current -62.61% should be judged against Healthcare norms (sector average: 22.13%) and against PLYX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -62.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.13%. From there, open related valuation or income-statement pages for Polaryx Therapeutics Common Stock, and consider following PLYX for alerts when major investors trade the stock.
Polaryx Therapeutics Common Stock is classified in the Healthcare sector. On ROE, it currently shows -62.61% versus a sector average near 22.13%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLYX with unrelated industries.
